Form 8-K - Current report:
SEC Accession No. 0001437749-21-022779
Filing Date
2021-09-28
Accepted
2021-09-28 16:30:49
Documents
16
Period of Report
2021-09-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20210927_8k.htm   iXBRL 8-K 40803
2 EXHIBIT 2.1 ex_286899.htm EX-2.1 705540
3 EXHIBIT 99.1 ex_286915.htm EX-99.1 19289
8 nbp01.jpg GRAPHIC 4957
  Complete submission text file 0001437749-21-022779.txt   1044241

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nby-20210927.xsd EX-101.SCH 3585
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20210927_def.xml EX-101.DEF 11421
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20210927_lab.xml EX-101.LAB 15310
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20210927_pre.xml EX-101.PRE 11581
9 EXTRACTED XBRL INSTANCE DOCUMENT nby20210927_8k_htm.xml XML 2569
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 211287303
SIC: 2834 Pharmaceutical Preparations